Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S
Formato:	Journal article
Publicado em:	Frontiers Media 2018

Registos relacionados

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
Por: Sarah Westwood, et al.
Publicado em: (2018-12-01)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
Por: Westwood, S, et al.
Publicado em: (2017)

New CSF biomarkers on the block
Por: Charlotte E Teunissen, et al.
Publicado em: (2016-09-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
Por: Rosha Babapour Mofrad, et al.
Publicado em: (2019-12-01)

Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
Por: Nevado-Holgado, A, et al.
Publicado em: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
Por: Eleonora M. Vromen, et al.
Publicado em: (2022-01-01)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
Por: Baird, A, et al.
Publicado em: (2015)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
Por: Alejo J Nevado-Holgado, et al.
Publicado em: (2017-01-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
Por: Betty Marije Tijms, et al.
Publicado em: (2021-08-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
Por: Yong-Jin Park, et al.
Publicado em: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
Por: Sanna Hellberg, et al.
Publicado em: (2019-03-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Por: Teunissen, C, et al.
Publicado em: (2018)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
Por: Lyduine E. Collij, et al.
Publicado em: (2023-11-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
Por: Si Eun Kim, et al.
Publicado em: (2020-01-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
Por: Eline A. J. Willemse, et al.
Publicado em: (2021-01-01)

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
Por: Stephanie J B Vos, et al.
Publicado em: (2014-01-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
Por: Yanaika S. Hok‐A‐Hin, et al.
Publicado em: (2023-07-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease
Por: Winchester, L, et al.
Publicado em: (2018)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
Por: Mark R. Battle, et al.
Publicado em: (2018-12-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
Por: Charlotte E. Teunissen, et al.
Publicado em: (2018-03-01)

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
Por: Vandenberghe, R, et al.
Publicado em: (2013)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
Por: Young-Sil An, et al.
Publicado em: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
Por: Taesik Yun, et al.
Publicado em: (2020-01-01)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
Por: Juhan Reimand, et al.
Publicado em: (2019-12-01)

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
Por: Westwood, S, et al.
Publicado em: (2016)

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
Por: Vandenberghe, R, et al.
Publicado em: (2010)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
Por: Hugh G. Pemberton, et al.
Publicado em: (2023-05-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
Por: Chan Ju Ryu
Publicado em: (2022-12-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
Por: Fiona Heeman, et al.
Publicado em: (2019-03-01)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
Por: Cullen, B, et al.
Publicado em: (2018)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
Por: Nevado-Holgado, A, et al.
Publicado em: (2016)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and CSF
Por: Winchester, L, et al.
Publicado em: (2022)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
Por: LEI Zhe, et al.
Publicado em: (2022-07-01)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
Por: Milos D. Ikonomovic, et al.
Publicado em: (2018-06-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
Por: Hiroshi Matsuda, et al.
Publicado em: (2021-01-01)

Blood based proteomic biomarkers of Alzheimer’s disease pathology
Por: Alison Louise Baird, et al.
Publicado em: (2015-11-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
Por: Carla M. Startin, et al.
Publicado em: (2019-03-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
Por: Laura M. Winchester, et al.
Publicado em: (2018-06-01)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
Por: Wesenhagen, KEJ, et al.
Publicado em: (2025)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
Por: Kirsten E. J. Wesenhagen, et al.
Publicado em: (2025-03-01)